Drugs / GSK3884464
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05044325 | Sep 2021 → Aug 2022 | heart failure | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3884464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05044325 ↗ |
| Route | Oral | “repeat oral doses of GSK3884464” NCT05044325 ↗ |